Dr Weranja Ranasinghe is an academic urologic-oncology surgeon with joint appointments at Monash University and Monash Health. Weranja graduated from the University of Bristol, UK in 2006 with a Bachelor of Medicine and Surgery (MBChB) degree and was awarded the MRCS diploma by the Royal College of Surgeons Edinburgh, UK in 2008. He received his PhD in Medicine and Health Sciences from the University of Melbourne, Australia in 2016 investigating the role of hypoxia in prostate cancer. He completed his Urology training in Australia and obtaining Fellowship to Royal Australasian College of Surgeons (FRACS Urol) in 2019. Following this, he also completed the Society of Uro-oncology fellowship at the University of Texas, MD Anderson Cancer Center, USA in 2021.

His primary research focus is on the patho-physiological processes of high risk, lethal and metastatic prostate cancers and pathways leading to treatment resistance. Expanding on his research on aggressive cancers and treatment resistance, his interest is in characterizing the biology of ductal prostate cancers, pathways driving development of metastases and the inherent mechanisms leading to adverse outcomes with conventional therapy.

His research experience has enabled him to build a strong academic record with numerous clinical and lab-based projects resulting in numerous publications in a number of prestigious peer reviewed journals and received multiple national and international awards and grant funding. One of his main strengths is the development of research collaborations which has led to several ongoing national and international collaborations with researchers, clinicians (urology, radiology, oncology etc.), basic scientists, epidemiologists and statisticians at MD Anderson (USA), University of Bristol (UK), Latrobe University and Austin Health.